AlloVir (AlloVir) Median PS Value : $0.00 (As of Jun. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is AlloVir Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. AlloVir's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0. AlloVir's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-06-05), AlloVir's share price is $0.78. AlloVir's Median PS Value is $0.00. Therefore, AlloVir's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for AlloVir's Median PS Value or its related term are showing as below:

ALVR's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

AlloVir Median PS Value Historical Data

The historical data trend for AlloVir's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Median PS Value Chart

AlloVir Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Median PS Value

Get a 7-Day Free Trial

AlloVir Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Median PS Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of AlloVir's Median PS Value

For the Biotechnology subindustry, AlloVir's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AlloVir's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlloVir's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where AlloVir's Price-to-Median-PS-Value falls into.

AlloVir Median PS Value Calculation

AlloVir's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0	*
	=	0.00

10-Year Median PS Ratio is .
AlloVir's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

AlloVir (NAS:ALVR) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

AlloVir's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	0.78	/	0.00
	=

AlloVir Median PS Value Related Terms

Thank you for viewing the detailed overview of AlloVir's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AlloVir (AlloVir) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.allovir.com

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

Executives

Vikas Sinha	director, 10 percent owner, officer: See Remarks	C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Edward Miller	officer: General Counsel	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen	officer: Chief Accounting Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams	director	ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B	officer: Chief Commercial Officer	C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy	officer: See Remarks	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal	director, 10 percent owner, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018